Federal Register / Vol. 72, No. 111 / Monday, June 11, 2007 / Notices 32123 

People 2010: Volumes I and II can be 

purchased by calling (202) 512–1800 

(cost $70.00 for printed version; $20.00 

for CD–ROM). Another reference is the 

Healthy People 2010 Final Review— 

2001. 

For one free copy of the Healthy 

People 2010, contact: The National 

Center for Health Statistics, Division of 

Data Services, 3311 Toledo Road, 

Hyattsville, MD 20782, or by telephone 

at (301) 458–4636. Ask for HHS 

Publication No. (PHS) 99–1256. This 

document may also be downloaded 

from: http://www.healthypeople.gov. 

3. Definitions 

For purposes of this announcement, 

the following definitions apply: 

Minority Populations—American 

Indian or Alaska Native; Asian; Black or 

African American; Hispanic or Latino; 

and Native Hawaiian or Other Pacific 

Islander (42 U.S.C. 300u–6, section 1707 

of the Public Health Service Act, as 

amended.) 

Multicultural Partnerships— 

Multicultural, multi-racial, and multiethnic entities comprising organizations 

and individuals that have come together 

for a common purpose and that function 

independently on behalf of the 

partnership’s members to address health 

disparities within communities of color. 

State and Territorial Office of 

Minority Health—An entity formally 

established by Executive Order, statute, 

or a state health officer to improve the 

health of racial and ethnic populations. 

Systems Change—An effort to ensure 

that the resources and infrastructure 

necessary are available and accessible to 

address minority health and health 

disparities as well as the public health 

and health care needs of the American 

population in general. Structural and 

functional components of the system 

must also be present—components such 

as information, data, and evaluation 

capabilities; trained, motivated, and 

culturally/linguistically appropriate 

staff; and facilities, equipment, and 

technologies appropriate for the needs 

of public health/health care 

professionals and the people they serve. 

Dated: June 5, 2007. 

Garth N. Graham, 

Deputy Assistant Secretary for Minority 

Health. 

[FR Doc. 07–2893 Filed 6–8–07; 8:45 am] 

BILLING CODE 4150–29–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Office of the Secretary 

Findings of Research Misconduct 

AGENCY: Office of the Secretary, HHS. 

ACTION: Notice. 

SUMMARY: Notice is hereby given that 

the Office of Research Integrity (ORI) 

and the Assistant Secretary for Health 

have taken final action in the following 

case: 

Wei Jin, Colorado State University: 

Based on an investigation conducted by 

Colorado State University (CSU) and 

additional analysis and information 

obtained by the Office of Research 

Integrity during its oversight review, the 

U.S. Public Health Service (PHS) found 

that Mr. Wei Jin, former doctoral 

candidate, Department of Chemistry, 

CSU, engaged in research misconduct in 

research funded by National Cancer 

Institutes (NCI), National Institutes of 

Health (NIH), grant R01 CA85419. 

Specifically, Mr. Jin falsified data/ 

results by claiming he had performed a 

novel total synthesis of renieramycin G, 

when in fact, he obtained renieramycin 

G through a relatively simple reaction 

sequence from renieramycin M, a 

natural product that was a gift to the 

laboratory and that had been isolated by 

others from the Thai sponge. Mr. Jin 

included the falsified data/results in: 

• His research notebooks and other 

records of his research; 

• His dissertation, ‘‘Asymmetric total 

synthesis of (¥)-Reineramycin G and 

studies toward the total synthesis of 

Ecteinascidin-743’’; 

• A manuscript, Jin, W. & Williams, 

R., ‘‘Asymmetric total synthesis of (¥)- 

Renieramycin G,’’ accepted by the 

Journal of the American Chemical 

Society; and 

• Supplemental information relative 

to the manuscript to be published 

online. 

ORI has implemented the following 

administrative actions for a period of 

three (3) years, beginning on May 8, 

2007: 

(1) Mr. Jin is debarred from eligibility 

for any contracting or subcontracting 

with any agency of the United States 

Government and from eligibility or 

involvement in nonprocurement 

programs of the United States 

Government referred to as ‘‘covered 

transactions’’ as defined in HHS’ 

implementation of OMB Guidelines to 

Agencies on Government-wide 

Debarment and Suspension at 2 CFR 

Part 376, et seq.; and 

(2) Mr. Jin is prohibited from serving 

in any advisory capacity to PHS, 

including but not limited to service on 

any PHS advisory committee, board, 

and/or peer review committee, or as a 

consultant. 

FOR FURTHER INFORMATION CONTACT: 

Director, Division of Investigative 

Oversight, Office of Research Integrity, 

1101 Wootton Parkway, Suite 750, 

Rockville, MD 20852, (240) 453–8800. 

John Dahlberg, 

Acting Director, Office of Research Integrity. 

[FR Doc. 07–2866 Filed 6–8–07; 8:45 am] 

BILLING CODE 4150–31–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

Request for Notification From Industry 

Organizations Interested in 

Participating in Selection Process for 

Nonvoting Industry Representatives on 

Food Safety Public Advisory 

Committee and Request for 

Nominations for Nonvoting Industry 

Representatives on Food Safety Public 

Advisory Committee 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) is requesting that 

any industry organizations interested in 

participating in the selection of 

nonvoting industry representatives to 

serve on its Food Advisory Committee 

for the Center for Food Safety and 

Applied Nutrition (CFSAN) notify FDA 

in writing. A nominee may either be 

self-nominated or nominated by an 

organization to serve as a nonvoting 

industry representative. Nominations 

will be accepted for current vacancies 

effective with this notice. 

DATES: Any industry organization 

interested in participating in the 

selection of an appropriate nonvoting 

member to represent industry interests 

must send a letter stating that interest to 

the FDA by July 11, 2007, for vacancies 

listed in this notice. Concurrently, 

nomination materials for prospective 

candidates should be sent to FDA by 

July 11, 2007. 

ADDRESSES: All letters of interest and 

nominations should be submitted in 

writing to Carolyn Jeletic (see FOR

FURTHER INFORMATION CONTACT). 

FOR FURTHER INFORMATION CONTACT: 

Carolyn Jeletic, Center for Food Safety 

and Applied Nutrition; Office of 

Regulations, Policy, and Social Sciences 

(HFS–24); Food and Drug 

Administration, 5100 Paint Branch 


rmajette on DSK8KYBLC1PROD with MISCELLANEOUS